13F Holdings
中文EN

PRPH ProPhase Labs, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 868278 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY138.9%
TTM net income YoY45.8%
TTM EPS YoY91.5%
Revenue 3-yr CAGR-63.4%
Net income 3-yr CAGR—

Margins

Gross margin16.8%
Operating margin-404.5%
Net margin-583.9%
FCF margin—
EBITDA margin-320.1%

Returns

ROE-539.7%
ROA-45.2%
ROIC (approx.)-302.2%
Asset turnover0.08x

Leverage & solvency

Liabilities / assets105.4%
Debt / equity—
Current ratio0.05x
Interest coverage-2.15x

Cash quality & payout

Operating cash flow / net income0.25x
Accruals ratio-34.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$4.34M$6.77M$34.98M$122.65M$79.04M
Cost of revenue$2.96M$6.92M$19.43M$51.99M$37.05M
Gross profit$1.38M-$150,000$15.56M$70.65M$41.99M
R&D expense$107,000$594,000$1.40M$652,000$520,000
SG&A expense$19.32M$37.88M$33.44M$34.38M$22.49M
Operating income-$18.05M-$38.63M-$21.22M$23.59M$9.80M
Interest expense$6.93M$3.35M$1.27M$764,000$1.15M
Pretax income-$23.39M-$42.33M-$22.40M$22.91M$5.30M
Income tax$0$7.20M-$6.02M$4.45M-$968,000
Net income-$14.74M-$53.36M-$16.78M$18.46M$6.27M
EBITDA-$13.21M-$32.44M-$15.17M$28.31M$13.04M
EPS (basic)-1.74-26.68-0.981.170.41
EPS (diluted)-1.74-26.68-0.981.020.40
Dividends declared per share————0.30
Weighted avg. shares (diluted)8.49M2.00M17.21M18.65M18.39M
Banking
Provision for credit losses—$0$91,000$6.16M—
Balance sheet
Cash & equivalents$90,000$678,000$1.61M$9.11M$8.66M
Short-term investments$0$3.13M$3.13M$8.33M$8.78M
Receivables$1.54M$20.06M$35.81M$37.05M$37.71M
Inventory$70,000$1.14M$2.29M$3.98M$4.60M
Current assets$3.15M$30.64M$47.59M$60.83M$61.32M
PP&E, net$2.03M$7.50M$10.33M$7.29M$5.95M
Goodwill$3.97M$5.23M$5.23M$5.71M$5.71M
Intangibles$7.17M$9.75M$12.33M$8.47M$10.85M
Total assets$59.87M$63.20M$91.93M$87.65M$89.30M
Current liabilities$53.08M$32.13M$20.86M$16.07M$15.52M
Short-term debt—$3.21M$0——
Long-term debt——$2.92M$0—
Total debt——$2.92M$0—
Total liabilities$56.36M$55.85M$42.54M$24.02M$30.67M
Shareholders' equity$3.51M$7.35M$49.38M$63.63M$58.63M
Net debt——$1.31M-$9.11M—
Shares outstanding8.97M2.99M18.05M16.21M15.49M
Cash flow statement
Operating cash flow-$8.34M-$17.54M-$11.89M$28.55M-$13.62M
Capital expenditure$0$906,000$2.08M$3.92M$4.23M
Free cash flow-$8.34M-$18.44M-$13.97M$24.63M-$17.85M
Investing cash flow$920,000$2.42M-$1.37M-$2.08M-$19.67M
Financing cash flow$6.84M$14.19M$5.76M-$26.02M$35.13M
Depreciation & amortization$4.83M$6.19M$6.05M$4.72M$3.23M
Stock-based compensation$1.89M$3.64M$3.54M$3.99M$3.18M
Dividends paid——$0$9.35M$4.55M
Share buybacks—$0$588,000$2.15M$917,000

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.